New cell therapy offers hope for severe IBD patients who have failed other treatments
NCT ID NCT07416383
First seen Feb 19, 2026 · Last updated Jun 05, 2026 · Updated 13 times
Summary
This early-stage study tests a new cell therapy called CNK-UT009 in 40 people with severe inflammatory bowel disease (Crohn's or colitis) that hasn't improved with standard treatments. The main goal is to check safety and find the best dose, while also looking at how well it works. Participants receive a single injection of these immune cells, which are designed to calm the overactive immune response causing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.